Every 10-Q that Inspire Medical Systems, Inc. (INSP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INSP filings page.
Inspire Medical Systems reported Q3 2025 growth with lower profitability. Revenue rose to $224.5 million from $203.2 million as U.S. sales remained the core driver. Gross profit reached $192.7 million, but higher operating costs, including advertising and SG&A, reduced operating income to $9.6 million from $14.3 million.
Net income was $9.9 million versus $18.5 million a year ago, with diluted EPS of $0.34 versus $0.60. For the first nine months, revenue was $642.9 million and net income was $9.3 million. Cash and cash equivalents were $112.8 million, with $209.7 million in short-term investments. Inventories increased to $141.8 million from $80.1 million, reflecting production and demand planning.
The company continued capital returns: it completed an accelerated share repurchase totaling 409,043 shares at an average price of $190.29, repurchased 442,649 shares for $75.0 million earlier in 2025, and bought 552,423 shares for $50.0 million under a new $200.0 million program, leaving $150.0 million authorized. Shares outstanding were 29,053,367 at September 30, 2025.